Get the Stockscreener App
0.7802
208.99%
0.5277
Genprex Inc stock is traded at $0.7802, with a volume of 798.05M.
It is up +208.99% in the last 24 hours and up +183.61% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.2525
Open:
$0.4796
24h Volume:
798.05M
Relative Volume:
38.26
Market Cap:
$33.75M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0666
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+219.36%
1M Performance:
+183.61%
6M Performance:
+200.08%
1Y Performance:
+132.41%
1-Day Range:
$0.456
$1.10
1-Week Range:
$0.17
$1.10
52-Week Range:
$0.14
$3.97
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.7867 | 10.83M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.87 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.42 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.86 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.20 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
315.17 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Gene Therapy Stock Genprex, Inc. (NASDAQ: GNPX) Makes Nasdaq Top Gainers List on News of Positive Preclinical Data on the Use of Reqorsa - Investorideas.com
Genprex (GNPX) Stock Soars on Lung Cancer Gene Therapy Data - parameter.io
Evaluating Genprex Inc. with trendline analysisTrade Performance Summary & Precise Swing Trade Alerts - newser.com
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough - ts2.tech
Will Genprex Inc. stock deliver consistent dividends2025 Key Lessons & High Accuracy Investment Signals - newser.com
Key metrics from Genprex Inc.’s quarterly dataJuly 2025 Drop Watch & Advanced Technical Signal Analysis - newser.com
Genprex (GNPX) Shares Jump 41% After Hours Following New Cancer Therapy Data - Benzinga
Why Genprex Inc. stock is popular among millennialsWeekly Trend Recap & Real-Time Buy Signal Alerts - newser.com
How Genprex Inc. stock responds to policy changesEarnings Recap Report & Verified Chart Pattern Signals - newser.com
What institutional flow reveals about Genprex Inc.July 2025 Opening Moves & Stock Market Timing Techniques - newser.com
Is now a turning point for Genprex Inc.Weekly Trend Report & Entry Point Strategy Guides - newser.com
Pre-market Movers: GNPX, BFRI, DBVT See Big Swings - RTTNews
10–33x tumor uptake: Genprex's REQORSA shows targeted TUSC2 delivery in preclinical poster on Oct 25 - Stock Titan
Using portfolio simulators with Genprex Inc. includedMarket Risk Summary & Technical Buy Zone Confirmations - newser.com
How to forecast Genprex Inc. trends using time seriesPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
Heatmap analysis for Genprex Inc. and competitorsJuly 2025 Catalysts & Growth Focused Entry Point Reports - newser.com
What to expect from Genprex Inc. in the next 30 daysJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Is Genprex Inc. still worth holding after the dipQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
How high can Genprex Inc. stock goMarket Movers & Growth Focused Stock Pick Reports - newser.com
Can Genprex Inc. stock resist market sell offsJuly 2025 Outlook & Long-Term Investment Growth Plans - newser.com
Is Genprex Inc. (2DE0) stock a top hedge fund pickTrade Entry Report & High Conviction Trade Alerts - newser.com
Analyzing net buyer seller activity in Genprex Inc.2025 Sector Review & Growth Oriented Trade Recommendations - newser.com
Risk vs reward if holding onto Genprex Inc.Market Volume Summary & Expert Curated Trade Setups - newser.com
Non-Viral Transfection Reagents Industry Report 2025, with Profiles of Altogen Biosystems, BEX, BTX, Celsion, Genprex, Inovio Pharmaceuticals, MaxCyte, MilliporeSigma, Nepa Gene, OZ Biosciences & MoreResearchAndMarkets.com - FinancialContent
Is Genprex Inc a good long term investmentDividend Stock Watch & Superior Wealth Strategies - earlytimes.in
What analysts say about Genprex Inc stockRetail Investor Activity & Invest Now – Opportunity Window Closing - earlytimes.in
What drives Genprex Inc 2DE0 stock priceIPO Market Watch & Claim Your Custom Stock Report Now - earlytimes.in
Using economic indicators to assess Genprex Inc. potentialEarnings Recap Report & Low Risk Entry Point Tips - newser.com
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.56%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):